BRAF and melanoma: Anti-programmed death 1 (PD-1) antibodies, either alone or in combination with an anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody, have been used in the treatment of BRAF-mutant melanoma.